William Blair Has Optimistic Outlook of KZR FY2024 Earnings
Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects ...
Lupus Foundation of America5d
Lupus Foundation of America Latest Research Achievements to be Featured at the 2024 American College of Rheumatology Annual Meeting
The Lupus Foundation of America (LFA), along with numerous researchers funded by the Foundation, will present novel lupus discoveries as part of the American College of Rheumatology Convergence 2024 ...
Yahoo Finance6d
Kezar struck again with second FDA hold
The FDA told the San-Francisco based biotech to halt the PALIZADE study (NCT05781750), a Phase IIb trial investigating ...
BioSpace6d
Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months
Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...
FierceBiotech6d
FDA hits Kezar's zetomipzomib program with 2nd clinical hold in 2 months
The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...
Business Wire6d
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...